Home » Topics » BioWorld Science

BioWorld Science
RSS

Adenosine A2A/A2B antagonists patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Jan. 30, 2020

Guangzhou Wellhealth Bio-Pharmaceutical discloses new PD-1/PD-L1 inhibitors

Jan. 30, 2020

Novel coronavirus emerges rapidly; so does science

Jan. 30, 2020

Phase II data presented for BPM-31510 plus gemcitabine in advanced PDAC

Jan. 30, 2020

Pfizer presents phase I data for PF-04518600 in HCC

Jan. 30, 2020

H84T engineered banana lectin shows efficacy in influenza virus infection models

Jan. 30, 2020

Unum provides update on phase I study of ACTR-707 plus trastuzumab

Jan. 30, 2020

Positive preliminary data from first patient in diverticulosis pilot trial of PGLG

Jan. 30, 2020

Spring Bank discontinues development of inarigivir and all HBV programs

Jan. 30, 2020

AgeX Therapeutics collaborates with Japanese biopharma to generate hypoimmunogenic cells

Jan. 30, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...